ANKLE2
protein-codingankyrin repeat and LEM domain containing 2, the group of Ankyrin repeat domain containing|LEM domain containing
Gene summary
This gene encodes a member of the LEM family of inner nuclear membrane proteins. The encoded protein functions as a mitotic regulator through postmitotic formation of the nuclear envelope. Mutations in this gene cause morphology defects in the nuclear envelope and BAF hyperphosphorylation. [provided by RefSeq, Mar 2014]
- KIAA0692
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~36.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0016660
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0014730
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014730
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0014730
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Craniofacial; Dermatologic; Neurologic; Ophthalmologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ANKLE2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_015114.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 31 | 4 | 36 | ||
| missense | 3 | 171 | 44 | 218 | ||
| nonsense | 2 | 2 | 4 | 8 | ||
| start loss | 0 | |||||
| frameshift | 1 | 2 | 3 | |||
| splice donor/acceptor (+/-2bp) | 1 | 1 | 6 | 8 | ||
| Total | 3 | 7 | 184 | 75 | 4 | 273 |
Highest pathogenic variant AF is 0.00002328241
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_055929.1 | 13 | MANE Select | |
| Ensembl | ENSP00000350686.5 | 13 | MANE Select | |
| Ensembl | ENSP00000437585.2 | 3 | Standard | |
| Ensembl | ENSP00000445760.1 | 3 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Initiation of Nuclear Envelope Reformation
- Nuclear Envelope Reassembly
- Mitotic Anaphase
- Mitotic Metaphase and Anaphase
- M Phase
Biological Process
- mitotic nuclear envelope reassembly
- central nervous system development
- positive regulation of protein dephosphorylation
- negative regulation of phosphorylation
- negative regulation of apoptotic process
Molecular Function
- protein binding
- protein phosphatase regulator activity
- protein phosphatase 2A binding
Cellular Component
- endoplasmic reticulum
- endoplasmic reticulum membrane
- membrane
- integral component of endoplasmic reticulum membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000357997
- Coding exons
- 13
- Length
- 36221
- Individuals with no LoFs
- 124777
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 85
- Defined
- 124862
- p
- 0.000340
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.343 | 509 | 531 | 0.958 | 0.0000318 | 6073 |
| Missense (PolyPhen) | 139 | 154.97 | 0.89697 | 1874 | ||
| Synonymous | -1.18 | 247 | 224 | 1.10 | 0.0000157 | 1898 |
| Loss of Function | 2.29 | 22 | 37.1 | 0.593 | 0.00000204 | 469 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00020 | 0.00019 | rare |
| Latino/Admixed American | 0.00021 | 0.00020 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00040 | 0.00039 | rare |
| Finnish | 0.00023 | 0.00023 | rare |
| European (Non-Finnish) | 0.00035 | 0.00034 | rare |
| South Asian | 0.00091 | 0.00072 | rare |
| Other | 0.00033 | 0.00033 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Involved in mitotic nuclear envelope reassembly by promoting dephosphorylation of BAF/BANF1 during mitotic exit. Coordinates the control of BAF/BANF1 dephosphorylation by inhibiting VRK1 kinase and promoting dephosphorylation of BAF/BANF1 by protein phosphatase 2A (PP2A), thereby facilitating nuclear envelope assembly. It is unclear whether it acts as a real PP2A regulatory subunit or whether it is involved in recruitment of the PP2A complex. Involved in brain development (PubMed:25259927). {ECO:0000269|PubMed:22770216, ECO:0000269|PubMed:25259927}.;
- Disease
- DISEASE: Microcephaly 16, primary, autosomal recessive (MCPH16) [MIM:616681]: A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age, sex and ethnically matched mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. {ECO:0000269|PubMed:25259927}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Intolerance Scores
- LoFtool
- 0.805
- RVIS EVS
- -0.08
- RVIS percentile EVS
- 47.22
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.644
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | High |
| Cancer | Medium | Medium | High |